TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma

Cancer Journal from Scientific American

Volumn 3, Issue 6, 1997, Pages 364-370

  Hsueh, Eddy C ^a   Gupta, Rishab K ^a   Qi, Karen ^a   Yee, Reynold ^a   Leopoldo, Zacarias C ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Active immunotherapy; Cancer vaccines; Melanoma metastasis; Prognosis; Tumor markers

Indexed keywords

GLYCOPROTEIN; MELANOMA VACCINE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGEN-ANTIBODY COMPLEX; CANCER VACCINES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0031440068     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193-201.
2. Balch CM, Soong SJ, Murad TM et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126-134.
3. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993;71:2995-3005.
4. Sirott MN, Bajorin DF, Wong GYC et al. Prognostic factors in patients with metastatic malignant melanoma. Cancer 1993;72: 3091-3098.
5. Roses DF, Karp NS, Oratz R et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 1991;172:262-268.
6. Tartour E, Blay JY, Dorval T et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 1996;14:1697-1703.
7. Gupta RK, Morton DL. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992;6:329-336.
8. Kelley M, Jones RJ, Gupta RK et al. Tumor-associated antigen TA90 predicts recurrence, lymph node status, and survival in stage I and II melanoma. Presented at the Society of Surgical Oncology Annual Meeting; March 1996; Atlanta, GA.
9. Tafra L, Dale PS, Wanek LA et al. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995;110:119-129.
10. Ollila DW, Essner R, Wanek LA et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 1996;131: 975-980.
11. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
12. Nabel GJ, Nabel EG, Yang ZY et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 1993;90:11307-11311.
13. Morton DL, Foshag LJ, Hoon DSB et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
14. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-244.
15. Wibe E, Paus E, Aamdal S. Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Cancer Lett 1990;52: 29-31.
16. Guo HB, Stoffel-Wagner B, Bierwirth T et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995;31A:1898-1907.
17. Scheibenbogen C, Mohler T, Haefele J et al. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995;5:179-181.
18. Sonesson B, Eide S, Ringborg U et al. Tyrosinase activity in the serum of patients with malignant melanoma. Melanoma Res 1995; 5:113-116.
19. Dummer W, Becker JC, Schwaaf A et al. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995;5:67-68.
20. Kageshita T, Yoshi A, Kimura T et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 1993;53:4927-4932.
21. Harning R, Mainolfi E, Bystryn J et al. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 1991;51:5003-5005.
22. Silver HKB, Karim KA, Le Riche J et al. Nuclear DNA, serum sialic acid and measured depth in malignant melanoma for predicting disease recurrence and survival. Int J Cancer 1989;44: 31-34.
23. Hara H, Walsh N, Yamada K et al. High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma. J Invest Dermatol 1994;102:501-505.